Literature DB >> 1998958

Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-1 gene deletions in human glial tumors.

C D James1, J He, E Carlbom, M Nordenskjold, W K Cavenee, V P Collins.   

Abstract

We have applied restriction fragment length polymorphism analysis to a 30-member panel of primary glioma DNAs, which had been previously examined for loss of genetic information (C. D. James, E. Carlbom, J. P. Dumanski, M. Hansen, M. Nordenskjold, V. P. Collins, and W. K. Cavenee, Cancer Res., 48:5546-5551, 1988), to determine the frequency and sublocalization of loss of genetic information from chromosome 9. We have also utilized scanning densitometry for dosage determination of the 9p-localized interferon alpha and interferon beta-1 genes among these same tumors. Our results reveal the following: (a) for those cases in which loss has occurred, the region of common loss lies on the short (p) arm of the chromosome; (b) loss of genetic information from the short arm of chromosome 9 occurs frequently in glial tumors of intermediate (anaplastic, grade III) and high (glioblastoma, grade IV) histological malignancy (10 of 20 cases) but not in tumors of low (grade II) histological malignancy (0 of 10 cases); (c) tumors with 9p deletions are hemi- or nullizygous for interferon beta-1 and the interferon alpha gene cluster; (d) cases of interferon nullizygosity occur exclusively among tumors of highest histological malignancy (glioblastoma). These data, especially the determination of a region of nullizygosity, suggest proximity to or residence within a gene(s) whose function(s) is (are) critical to the suppression of the malignant evolution of glial tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1998958

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations.

Authors:  David M Roy; Logan A Walsh; Alexis Desrichard; Jason T Huse; Wei Wu; JianJiong Gao; Promita Bose; William Lee; Timothy A Chan
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

2.  DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.

Authors:  Kazuo Okemoto; Kazue Kasai; Benjamin Wagner; Amy Haseley; Hans Meisen; Chelsea Bolyard; Xiaokui Mo; Allison Wehr; Amy Lehman; Soledad Fernandez; Balveen Kaur; E Antonio Chiocca
Journal:  Clin Cancer Res       Date:  2013-09-20       Impact factor: 12.531

Review 3.  The application of 5-bromodeoxyuridine in the management of CNS tumors.

Authors:  A Freese; D O'Rourke; K Judy; M J O'Connor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 4.  Genetic alterations in glioma and medulloblastoma.

Authors:  B K Rasheed; S H Bigner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

Review 5.  Genetics of cancer predisposition and progression.

Authors:  K Schwechheimer; W K Cavenee
Journal:  Clin Investig       Date:  1993-06

6.  Mutations and altered expression of p16INK4 in human cancer.

Authors:  A Okamoto; D J Demetrick; E A Spillare; K Hagiwara; S P Hussain; W P Bennett; K Forrester; B Gerwin; M Serrano; D H Beach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

7.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

8.  Aggregation of cancer in first-degree relatives of patients with glioma.

Authors:  Michael E Scheurer; Carol J Etzel; Mei Liu; Randa El-Zein; Gladstone E Airewele; Beatrice Malmer; Kenneth D Aldape; Jeffrey S Weinberg; W K Alfred Yung; Melissa L Bondy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-11       Impact factor: 4.254

Review 9.  Molecular cytogenetic quantitation of gains and losses of genetic material from human gliomas.

Authors:  B G Feuerstein; G Mohapatra
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

10.  Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

Authors:  M D Groves; V K Puduvalli; M R Gilbert; V A Levin; C A Conrad; V H Liu; K Hunter; C Meyers; K R Hess; W K Alfred Yung
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.